A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
Public ClinicalTrials.gov record NCT04840199. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who were on antiretroviral therapy (ART)-mediated suppression. Participants were randomly assigned to receive either letermovir once daily or no anti-CMV treatment, for 48 weeks. The primary hypothesis of this study was that letermovir would cause a greater reduction in plasma soluble receptor for tumor necrosis factor type II (sTNFRII) levels than no anti-CMV treatment at weeks 46/48.
Study identification
- NCT ID
- NCT04840199
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 44 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2022
- Primary completion
- Nov 29, 2023
- Completion
- Nov 29, 2023
- Last update posted
- Mar 3, 2025
2022 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD Antiviral Research Center CRS (Site 701) | San Diego | California | 92103 | — |
| UCSF HIV/AIDS CRS (Site 801) | San Francisco | California | 94110 | — |
| University of Colorado Hospital CRS | Aurora | Colorado | 80045 | — |
| Northwestern University CRS | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital CRS (MGH CRS) | Boston | Massachusetts | 02114 | — |
| Washington University Therapeutics (WT) CRS | St Louis | Missouri | 63110 | — |
| Weill Cornell Chelsea CRS (7804) | New York | New York | 10010 | — |
| Weill Cornell Uptown CRS (7803) | New York | New York | 10065 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS | Rochester | New York | 14642 | — |
| Cincinnati Clinical Research Site | Cincinnati | Ohio | 45267 | — |
| Case Clinical Research Site | Cleveland | Ohio | 44106 | — |
| Penn Therapeutics, CRS | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh CRS | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Therapeutics (VT) CRS | Nashville | Tennessee | 37204 | — |
| University of Washington Positive Research CRS | Seattle | Washington | 98104-9929 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04840199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04840199 live on ClinicalTrials.gov.